A case of oxaliplatin-related posterior reversible encephalopathy syndrome.
We report the first case of oxaliplatin-related posterior reversible encephalopathy syndrome (PRES) in the medical literature. A 19-year-old woman with metastatic adenocarcinoma of the rectum received modified FOLFOX (5-fluorouracil/oxaliplatin) chemotherapy. Ten days after the fourth treatment, she presented to the hospital with seizures and altered mental status. Magnetic resonance imaging of the brain demonstrated hyperintensity in the white matter of the posterior hemispheres consistent with PRES. Herein, we briefly review the PRES syndrome and its management.
Skelton
Matthew R
MR
Division of Hematology and Oncology, University of North Carolina at Chapel Hill, NC 27599-7305, USA.
Goldberg
Richard M
RM
O'Neil
Bert H
BH
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001927:Brain Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013577:Syndrome
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin